The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
mTOR inhibitors in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Guertin, D. A., Stevens, D. M., Thoreen, C. C., Burds, A. A., Kalaany, N. Y., Moffat, J., Brown, M., Fitzgerald, K. J., & Sabatini, D. M. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.007 · Cited by 1,415
SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth
Porstmann, T., Santos, C. R., Griffiths, B., Cully, M., Wu, M., Leevers, S., Griffiths, J. R., Chung, Y.-L., & Schulze, A. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.07.007 · Cited by 1,413
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Peterson, T. R., Laplante, M., Thoreen, C. C., Sancak, Y., Kang, S. A., Kuehl, W. M., Gray, N. S., & Sabatini, D. M. (2009) · Cell · doi:10.1016/j.cell.2009.03.046 · Cited by 1,202
Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
García-Martínez, J. M., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20081668 · Cited by 907
Yu, Y., Yoon, S.-O., Poulogiannis, G., Yang, Q., Ma, X. M., Villén, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., et al. (2011) · Science · doi:10.1126/science.1199484 · Cited by 854
Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P., & Blenis, J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809136105 · Cited by 810
Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J. A., Valero, V., Guzman, M., Botero, M. L., Llonch, E., Atzori, F., Di Cosimo, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1385 · Cited by 787
Activation of mTORC2 by Association with the Ribosome
Zinzalla, V., Stracka, D., Oppliger, W., & Hall, M. N. (2011) · Cell · doi:10.1016/j.cell.2011.02.014 · Cited by 654
mTOR Is Essential for Growth and Proliferation in Early Mouse Embryos and Embryonic Stem Cells
Murakami, M., Ichisaka, T., Maeda, M., Oshiro, N., Hara, K., Edenhofer, F., Kiyama, H., Yonezawa, K., & Yamanaka, S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6710-6718.2004 · Cited by 624
An Emerging Role of mTOR in Lipid Biosynthesis
Laplante, M., & Sabatini, D. M. (2009) · Current Biology · doi:10.1016/j.cub.2009.09.058 · Cited by 620
Akt Maintains Cell Size and Survival by Increasing mTOR-dependent Nutrient Uptake
Edinger, A. L., & Thompson, C. B. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-12-0584 · Cited by 589
The Pharmacology of mTOR Inhibition
Guertin, D. A., & Sabatini, D. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe24 · Cited by 568
Gulhati, P., Bowen, K. A., Liu, J., Stevens, P. D., Rychahou, P. G., Chen, M., Lee, E. Y., Weiss, H. L., O'Connor, K. L., Gao, T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4058 · Cited by 543
Self-citationMammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
Regulation of eIF-4E BP1 Phosphorylation by mTOR
Hara, K., Yonezawa, K., Kozlowski, M. T., Sugimoto, T., Andrabi, K., Weng, Q.-P., Kasuga, M., Nishimoto, I., & Avruch, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26457 · Cited by 527
Gangloff, Y.-G., Mueller, M., Dann, S. G., Svoboda, P., Sticker, M., Spetz, J.-F., Um, S. H., Brown, E. J., Cereghini, S., Thomas, G., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9508-9516.2004 · Cited by 485
mTOR and cancer: many loops in one pathway
Efeyan, A., & Sabatini, D. M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.10.007 · Cited by 430
Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A. P., Dabora, S. L., Griffin, J. D., & Kwiatkowski, D. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28984 · Cited by 381
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
Guertin, D. A., Stevens, D. M., Saitoh, M., Kinkel, S., Crosby, K., Sheen, J.-H., Mullholland, D. J., Magnuson, M. A., Wu, H., & Sabatini, D. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.017 · Cited by 355
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. (2007) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 342
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
Janes, M. R., Limon, J. J., So, L., Chen, J., Lim, R. J., Chavez, M. A., Vu, C., Lilly, M. B., Mallya, S., Ong, S. T., et al. (2010) · Nature Medicine · doi:10.1038/nm.2091 · Cited by 337
Common corruption of the mTOR signaling network in human tumors
Menon, S., & Manning, B. D. (2008) · Oncogene · doi:10.1038/onc.2009.352 · Cited by 332
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Targeting the mTOR signaling network in cancer
Chiang, G. G., & Abraham, R. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.08.001 · Cited by 327
Morrisett, J. D., Abdel-Fattah, G., Hoogeveen, R., Mitchell, E., Ballantyne, C. M., Pownall, H. J., Opekun, A. R., Jaffe, J. S., Oppermann, S., & Kahan, B. D. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m100392-jlr200 · Cited by 295
Masri, J., Bernath, A., Martin, J., Jo, O. D., Vartanian, R., Funk, A., & Gera, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2223 · Cited by 253
Manning, B. D., & Cantley, L. C. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310573 · Cited by 210
Gibbons, J. J., Abraham, R. T., & Yu, K. (2009) · Seminars in Oncology · doi:10.1053/j.seminoncol.2009.10.011 · Cited by 208
Gulhati, P., Cai, Q., Li, J., Liu, J., Rychahou, P. G., Qiu, S., Lee, E. Y., Silva, S. R., Bowen, K. A., Gao, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1249 · Cited by 177
Self-citationmTOR mediated anti-cancer drug discovery
Liu, Q., Thoreen, C., Wang, J., Sabatini, D., & Gray, N. S. (2009) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2009.12.001 · Cited by 174
Transcriptional Control of Cellular Metabolism by mTOR Signaling
Yecies, J. L., & Manning, B. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4158 · Cited by 162
Functional Genomics Identifies TOR-Regulated Genes that Control Growth and Division
Guertin, D. A., Guntur, K. V. P., Bell, G. W., Thoreen, C. C., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.03.084 · Cited by 158
Targeting mTOR globally in cancer: Thinking beyond rapamycin
Shor, B., Gibbons, J. J., Abraham, R. T., & Yu, K. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10070 · Cited by 157
Liu, L., Luo, Y., Chen, L., Shen, T., Xu, B., Chen, W., Zhou, H., Han, X., & Huang, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.141168 · Cited by 145
Decreased Lymphangiogenesis and Lymph Node Metastasis by mTOR Inhibition in Head and Neck Cancer
Patel, V., Marsh, C. A., Dorsam, R. T., Mikelis, C. M., Masedunskas, A., Amornphimoltham, P., Nathan, C. O., Singh, B., Weigert, R., Molinolo, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3192 · Cited by 144
Gedaly, R., Angulo, P., Hundley, J. C., Daily, M. F., Chen, C., Koch, A., & Evers, B. M. (2010) · PubMed · Cited by 143
Roper, J., Richardson, M. P., Wang, W. V., Richard, L. G., Chen, W., Coffee, E. M., Sinnamon, M. J., Lee, L., Chen, P., Bronson, R. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025132 · Cited by 137
mTOR Complex Component Rictor Interacts with PKCζ and Regulates Cancer Cell Metastasis
Zhang, F., Zhang, X., Li, M., Chen, P., Zhang, B., Guo, H., Cao, W., Wei, X., Cao, X., Hao, X., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0207 · Cited by 137
Raptor and mTOR: Subunits of a Nutrient-Sensitive Complex
Kim, D., & Sabatini, D. M. (2004) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-18930-2_15 · Cited by 134
Zask, A., Verheijen, J. C., Curran, K. J., Kaplan, J. A., Richard, D. J., Nowak, P., Malwitz, D. J., Brooijmans, N., Bard, J., Svenson, K., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900851f · Cited by 100
Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
Roulin, D., Cerantola, Y., Dormond-Meuwly, A., Demartines, N., & Dormond, O. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-57 · Cited by 88
Roulin, D., Waselle, L., Dormond-Meuwly, A., Dufour, M., Demartines, N., & Dormond, O. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-90 · Cited by 74
mTOR Signaling in Cancer Cell Motility and Tumor Metastasis
Zhou, H., & Huang, S. (2010) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v20.i1.10 · Cited by 70
Activating mutations of TOR (target of rapamycin)
Hardt, M. E., Chantaravisoot, N., & Tamanoi, F. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01482.x · Cited by 67
Combining EGFR and mTOR Blockade for the Treatment of Epithelioid Sarcoma
Xie, X., Ghadimi, M. P., Young, E. D., Belousov, R., Zhu, Q.-S., Liu, J., Lopez, G., Colombo, C., Peng, T., Reynoso, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0660 · Cited by 51
Zhao, H., Cui, K., Nie, F., Wang, L., Brandl, M., Jin, G., Li, F., Mao, Y., Xue, Z., Rodriguez, A. A., et al. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1420-7 · Cited by 49
Capdevila, J., Salazar, R., Halperín, I., Abad, A., & Yao, J. C. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9290-3 · Cited by 43
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Alvarado, Y., Mita, M. M., Vemulapalli, S., Mahalingam, D., & Mita, A. C. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0178-5 · Cited by 42
Li, J., Liu, J., Song, J., Wang, X., Weiss, H. L., Townsend, C. M., Gao, T., & Evers, B. M. (2011) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00067.2011 · Cited by 28
Blocking the mTOR pathway: a drug discovery perspective
García-Echeverría, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390451 · Cited by 25
Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer
Salazar, R., Reidy‐Lagunes, D. L., & Yao, J. C. (2011) · Drugs · doi:10.2165/11585500-000000000-00000 · Cited by 11
RNA interference targeting raptor inhibits proliferation of gastric cancer cells
Wu, W. K. K., Lee, C. W., Cho, C. H., Chan, F. K. L., Yu, J. Q., & Sung, J. J. �. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.03.005 · Cited by 8
Cited by
Rapamycin: one drug, many effects
Li, J., Kim, S. G., & Blenis, J. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.001 · Cited by 1,287
The critical role of Akt in cardiovascular function
Abeyrathna, P., & Su, Y. (2015) · Vascular Pharmacology · doi:10.1016/j.vph.2015.05.008 · Cited by 423
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
The Biology of Aging and Cancer: A Brief Overview of Shared and Divergent Molecular Hallmarks
Aunan, J. R., Cho, W. C., & Søreide, K. (2017) · Aging and disease · doi:10.14336/ad.2017.0103 · Cited by 373
Oncogenic Roles of the PI3K/AKT/mTOR axis
Aoki, M., & Fujishita, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_6 · Cited by 355
Metadata
- Authors
- Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., & Mark Evers, B.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 319
- Issue
- 1
- Pages
- 1-7
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W1969157667
- Cited by
- 291
- References
- 60
- FWCI
- 9.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.